Genome-wide association study identifies a potent locus associated with human opioid sensitivity.
D Nishizawa1, K Fukuda2, S Kasai1
1Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Molecular Psychiatry
|November 28, 2012
Summary
Genetic variations near the 2q33.3-2q34 region significantly impact how individuals respond to opioid pain relief and their susceptibility to substance dependence. This discovery aids personalized medicine for pain and addiction.
Area of Science:
- Pharmacogenomics
- Neuroscience
- Genetics
Background:
- Opioids are crucial for pain management but exhibit significant interindividual variability in efficacy and side effects.
- Existing genetic markers do not fully explain the wide range of human opioid sensitivity.
- The opioid system is integral to drug reward pathways, influencing susceptibility to addiction.
Purpose of the Study:
- To identify genetic factors contributing to interindividual differences in opioid sensitivity.
- To investigate the association between genetic polymorphisms and the need for opioid analgesics.
- To explore the link between genetic variations, substance dependence liability, and reward-related personality traits.
Main Methods:
- Conducted a multistage genome-wide association study (GWAS) in healthy subjects.
- Analyzed genetic polymorphisms in the 2q33.3-2q34 chromosomal region.
- Correlated single-nucleotide polymorphism (SNP) rs2952768 genotypes with postoperative analgesic requirements, substance dependence diagnoses, and personality scores.
Main Results:
- Genetic polymorphisms within the 2q33.3-2q34 locus, particularly SNP rs2952768, were strongly associated with opioid analgesic requirements.
- The C allele of rs2952768 correlated with increased analgesic needs and reduced vulnerability to severe drug dependence (methamphetamine, alcohol, eating disorders).
- The C/C genotype of rs2952768 was linked to higher expression of the neighboring CREB1 gene.
Conclusions:
- SNPs in the 2q33.3-2q34 locus represent potent genetic determinants of human opioid sensitivity.
- These findings highlight the dual role of this genetic locus in modulating both analgesic efficacy and addiction liability.
- The results offer valuable insights for developing personalized pain management and addiction treatment strategies.
Related Concept Videos
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...